Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label Feasibility Study of Daratumumab With Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV

NCT04139304 is registered in ClinicalTrials.gov with AIDS Malignancy Consortium as lead sponsor.

NCT NCT04139304
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04139304 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label Feasibility Study of Daratumumab With Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV
Lead sponsor
AIDS Malignancy Consortium
Phase
Phase 1
Overall status
Recruiting
Start date
May 24, 2021
Completion date
July 31, 2030
Enrollment
15 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

ann arbor stage i diffuse large b-cell lymphoma, ann arbor stage ii diffuse large b-cell lymphoma, ann arbor stage iii diffuse large b-cell lymphoma, ann arbor stage iv diffuse large b-cell lymphoma, plasmablastic lymphoma